Clinical trials
Tumor clinical trials
Below are recruiting tumor clinical trials, each written for real people, not researchers. We’re tracking 3,414 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06474676RecruitingPhase 1
Modified immune cell therapy for advanced sarcoma
This trial tests a new treatment using your own immune cells (TILs) that have been modified to attack sarcoma tumors. It is for people with advanced soft tissue or bone sarcoma who have already tried at least one other therapy.
Houston, TexasAges 12 years+ - NCT06478030Recruiting
Combined screening for stomach and bowel cancer
This study is testing a combined screening method for finding cancer in the stomach and intestines at an early stage. It is for people in Zhejiang Province who are willing to be screened and followed over time.
Jinhua, ZhejiangAges 40–74 - NCT06478108RecruitingPhase 2/Phase 3
Software-guided multi-immunotherapy for solid tumors
This trial tests a new software-guided approach to deliver multiple immunotherapy drugs directly into the liver for people with solid tumors. It aims to see if this method can shrink tumors and improve survival.
Guangzhou, GuangdongAges 18–75 - NCT06478251RecruitingPhase 1
Engineered immune cells for KRAS-mutated advanced solid tumors
This trial tests a new type of cell therapy that uses your own immune cells, specially trained to attack cancer cells with a KRAS G12V or G12D mutation. It may be an option if you have advanced solid tumors that no longer respond to standard treatments.
Hangzhou, ZhejiangAges 18–75 - NCT06484556RecruitingPhase 1
T cell therapy for KRAS-mutated advanced solid tumors
This trial tests a personalized T cell therapy designed to target cancer cells with specific KRAS mutations (G12V or G12D). It may be an option for people with advanced solid tumors who have exhausted standard treatments.
Wuhan, HubeiAges 18–75 - NCT06484790RecruitingPhase 1
Engineered T cell therapy for KRAS-mutated advanced solid tumors
This trial tests a personalized T cell therapy designed to target specific KRAS mutations (G12V or G12D) in people with advanced solid tumors who have no standard treatment options left. The treatment involves collecting your own immune cells, engineering them to recognize and attack cancer cells with these mutations, and then infusing them back into you.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06484816RecruitingPhase 1
TGRX-1942 study for advanced solid tumor or blood cancer
This trial tests an experimental drug (TGRX-1942) for people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goal is to find a safe dose and see how well the drug works.
Hangzhou, ZhejiangAges 18 years+ - NCT06484985RecruitingPhase 1
Testing AXT-1003 for advanced blood cancers and solid tumors
This trial tests a new drug (AXT-1003) for people with advanced blood cancers (like non-Hodgkin lymphoma) or solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.
BeijingAges 18 years+ - NCT07174583RecruitingPhase 1/Phase 2
Study of IDE849 for DLL3-positive cancers like SCLC
This trial tests a new drug called IDE849 for cancers that make a protein called DLL3, including small cell lung cancer and some neuroendocrine tumors. It is for people whose cancer has progressed after standard treatments, and may be given alone or combined with other drugs like durvalumab or IDE161.
Denver, ColoradoAges 18 years+ - NCT06486506Recruiting
Results of thigh bone replacement after bone tumor surgery
This study looks back at patients who had surgery to replace the top part of the thigh bone after a bone sarcoma. Researchers want to understand how well these surgeries worked over time.
Bologna, BOAges 18–90 - NCT06487624RecruitingPhase 1
Study of HCB301 for advanced solid tumors and Hodgkin lymphoma
This trial tests a new drug called HCB301, which targets proteins that help cancer hide from the immune system. It is for people with advanced solid tumors or classical Hodgkin lymphoma who have tried other treatments without success.
Greenville, South CarolinaAges 18 years+ - NCT06487663Recruiting
TACE plus immunotherapy for untreated liver cancer
This study tests combining TACE (a procedure to block the tumor's blood supply) with immunotherapy drugs for liver cancer that has not spread outside the liver. It is for people who have not had any prior treatment for their liver cancer and are healthy enough for TACE.
TianjinAges 18–75 - NCT06493864RecruitingPhase 1
BL-B16D1 for advanced breast cancer and solid tumors
This trial tests a new drug called BL-B16D1 for people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06495554Recruiting
Danish vulva cancer recurrence study
This study looks at how vulva cancer returns (recurrence) over time. It aims to improve follow-up care for people who have had this type of cancer.
Aarhus NAges 18 years+ - NCT06496373RecruitingEarly Phase 1
mRNA vaccine plus immunotherapy after pancreatic cancer surgery
This trial tests a personalized mRNA vaccine combined with an immunotherapy drug (PD-1 inhibitor) to prevent pancreatic cancer from returning after surgery. It is for patients whose tumors have specific genetic features and who cannot have standard chemotherapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06496971RecruitingPhase 3
Testing focused ultrasound plus Avastin for recurrent glioblastoma
This study tests whether adding focused ultrasound to the standard drug Avastin (bevacizumab) can help treat recurrent glioblastoma. The ultrasound may help more of the drug reach the tumor.
TaipeiAges 18–80 - NCT06500052RecruitingPhase 1
Study of BL-M17D1 for HER2-positive or low-expression digestive tract and other solid tumors
This trial tests a new drug called BL-M17D1 for people with advanced or metastatic HER2-positive or low-expression gastrointestinal cancer and other solid tumors. The goal is to see if it is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT06501521Recruiting
Non-invasive brain tumor testing and monitoring
This study is testing a new, non-invasive way to diagnose and monitor brain tumors. It may offer a less risky option compared to traditional biopsies.
OlomoucAges 18–99 - NCT06503783RecruitingPhase 1
Study of BL-M17D1 for advanced breast cancer and solid tumors
This trial tests a new drug, BL-M17D1, for people with advanced breast cancer (HER2 positive or negative) or other solid tumors that have spread. It aims to see if the drug is safe and effective.
Harbin, HeilongjiangAges 18–75 - NCT06508307RecruitingPhase 1
A study of an injected virus for advanced solid tumors
This trial tests a new treatment where a virus (GC001) is injected directly into a tumor. The virus is designed to attack cancer cells and may help people with advanced solid tumors that haven't responded to other treatments.
Zhengzhou, HenanAges 18–75 - NCT06514118Recruiting
Immunotherapy with radiation for advanced small-cell lung cancer
This trial tests a combination of chemotherapy, immunotherapy, and targeted radiation for people with extensive-stage small-cell lung cancer. The goal is to see if adding radiation to leftover tumors after initial treatment helps control the disease better.
Qingdao, ShandongAges 18–80 - NCT06521554RecruitingPhase 1
Study of NVL-330 for HER2-altered advanced lung cancer
This trial tests a new oral drug called NVL-330 for people with advanced NSCLC whose tumors have a specific change in the HER2 gene. The goal is to see if the drug can shrink or slow the growth of the cancer.
Irvine, CaliforniaAges 18 years+ - NCT06524557Recruiting
Ultrasound-based test to tell benign from malignant liver tumors
This study uses ultrasound images to help tell the difference between benign (non-cancerous) and malignant (cancerous) liver tumors without needing a needle biopsy. If you are 18–70, have a liver tumor visible on ultrasound, and are planning a biopsy or surgery to confirm the diagnosis, you may be able to join.
Xi'an, Xi'anAges 18–70 - NCT06528691RecruitingPhase 2
Entrectinib for young children with NTRK/ROS1 brain tumors
This trial tests a targeted drug (entrectinib) in very young children (under 3) with a newly diagnosed brain tumor that has a specific genetic change (NTRK or ROS1 fusion). The drug works by blocking signals that help the tumor grow, and is given as the first treatment, before any chemotherapy or radiation.
Memphis, TennesseeAges Up to 3 years
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor?
- Yes. Clin2 currently lists 3,414 recruiting tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.